eperezolid profile

ID Source	ID
PubMed CID	73214
CHEMBL ID	47955
SCHEMBL ID	186562
MeSH ID	M0257533

Synonym
acetamide, n-((3-(3-fluoro-4-(4-(hydroxyacetyl)-1-piperazynyl)phenyl)- 2-oxo-5-oxazolidinyl)methyl)-, (s)-
u-100592
eperezolid ,
165800-04-4
n-[[(5s)-3-[3-fluoro-4-[4-(2-hydroxyacetyl)piperazin-1-yl]phenyl]-2-oxo-oxazolidin-5-yl]methyl]acetamide
acetamide, n-((3-(3-fluoro-4-(4-(hydroxyacetyl)-1-piperazinyl)phenyl)-2-oxo-5-oxazolidinyl)methyl)-, (s)-
u 100592
n-(((s)-3-(3-fluoro-4-(4-glycoloyl-1-piperazinyl)phenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide
eperezolid [usan]
D04017
eperezolid (usan/inn)
CHEMBL47955
u-100,592
AKOS015951014
c460zsu1ow ,
unii-c460zsu1ow
eperezolid [usan:inn]
n-((3-(3-fluoro-4-(n-1-(4-hydroxyacetyl)piperazinyl)phenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide
bdbm50433368
HY-10393
SCHEMBL186562
eperezolid [who-dd]
n-[[(s)-3-[3-fluoro-4-(4-glycoloyl-1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
eperezolid [inn]
(s)-n-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]-phenyl]-2-oxo-5-oxazolidinyl]methyl]-acetamide
SIMWTRCFFSTNMG-AWEZNQCLSA-N
(s)-n-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1 -piperazinyl]-phenyl]-2-oxo-5-oxazolidinyl]methyl]-acetamide
(s)-n-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
DTXSID50168028
EX-A5272
NCGC00378601-01
(s)-n-((3-(3-fluoro-4-(4-(2-hydroxyacetyl)piperazin-1-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)acetamide
Q1346746
u100592
gtpl10803
comound 2 [pmid: 23584544]
MS-26621
pnu-100592pnu-100592

Excerpt	Reference	Relevance
"The objective of this study was to evaluate a physiologically based pharmacokinetic (PBPK) approach for predicting the plasma concentration-time curves expected after intravenous administration of candidate drugs to rodents."	( Evaluation of a basic physiologically based pharmacokinetic model for simulating the first-time-in-animal study. Burton, PS; Crivori, P; Germani, M; Poggesi, I; Rocchetti, M; Smith, ME; Wilson, AG, 2007)	0.34

Excerpt	Reference	Relevance
"The Upjohn oxazolidinones, U-100592 and U-100766, are orally bioavailable synthetic antimicrobial agents with spectra of activity against antibiotic-susceptible and -resistant gram-positive pathogens."	( In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections. Barbachyn, MR; Brickner, SJ; Ford, CW; Hamel, JC; Hutchinson, DK; Moerman, JK; Stapert, D; Wilson, DM; Yancey, RJ, 1996)	0.29
" Linezolid, the oxazolidinone which has been selected for clinical development, has near complete oral bioavailability plus favourable pharmacokinetic and toxicity profiles."	( Oxazolidinones: a review. Diekema, DI; Jones, RN, 2000)	0.31
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Excerpt	Relevance	Reference
" faecalis sera from patients dosed with either drug were generally inhibitory at the peak timepoint, but at trough only linezolid exhibited a persistent effect."	( Serum inhibitory titers and serum bactericidal titers for human subjects receiving multiple doses of the antibacterial oxazolidinones eperezolid and linezolid. Batts, DH; Daley-Yates, PT; Pawsey, SD; Schaadt, RD; Stalker, DJ; Zurenko, GE, 1997)	0.5
" A dose-response study was performed with PNU-100480 and linezolid (both at 25, 50, and 100 mg/kg of body weight)."	( Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Chase, S; Cynamon, MH; Klemens, SP; Sharpe, CA, 1999)	0.3
" At a dosage of 100 mg/kg/day, linezolid treatment led to an approximately 100-fold reduction in viable cells per gram of abscess."	( Activities of the oxazolidinones linezolid and eperezolid in experimental intra-abdominal abscess due to Enterococcus faecalis or vancomycin-resistant Enterococcus faecium. Eliopoulos, GM; Moellering, RC; Schülin, T; Thauvin-Eliopoulos, C, 1999)	0.56

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	37.9083	0.0123	7.9835	43.2770	AID1645841
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Cytochrome P450 1A2	Homo sapiens (human)	IC50 (µMol)	20.0000	0.0001	1.7740	10.0000	AID745377
Cytochrome P450 3A4	Homo sapiens (human)	IC50 (µMol)	20.0000	0.0001	1.7536	10.0000	AID745375
Cytochrome P450 2D6	Homo sapiens (human)	IC50 (µMol)	20.0000	0.0000	2.0151	10.0000	AID745376
Cytochrome P450 2C9	Homo sapiens (human)	IC50 (µMol)	20.0000	0.0000	2.8005	10.0000	AID745378
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
steroid catabolic process	Cytochrome P450 1A2	Homo sapiens (human)
porphyrin-containing compound metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
toxin biosynthetic process	Cytochrome P450 1A2	Homo sapiens (human)
post-embryonic development	Cytochrome P450 1A2	Homo sapiens (human)
alkaloid metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
regulation of gene expression	Cytochrome P450 1A2	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
dibenzo-p-dioxin metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 1A2	Homo sapiens (human)
lung development	Cytochrome P450 1A2	Homo sapiens (human)
methylation	Cytochrome P450 1A2	Homo sapiens (human)
monocarboxylic acid metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 1A2	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 1A2	Homo sapiens (human)
cellular respiration	Cytochrome P450 1A2	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
hydrogen peroxide biosynthetic process	Cytochrome P450 1A2	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 1A2	Homo sapiens (human)
cellular response to cadmium ion	Cytochrome P450 1A2	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 1A2	Homo sapiens (human)
lipid hydroxylation	Cytochrome P450 3A4	Homo sapiens (human)
lipid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
androgen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
calcitriol biosynthetic process from calciol	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 3A4	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
coumarin metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
isoquinoline alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of cellular organofluorine metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
arachidonic acid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
urea metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monocarboxylic acid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C9	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
amide metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
icosanoid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2C9	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
monooxygenase activity	Cytochrome P450 1A2	Homo sapiens (human)
iron ion binding	Cytochrome P450 1A2	Homo sapiens (human)
protein binding	Cytochrome P450 1A2	Homo sapiens (human)
electron transfer activity	Cytochrome P450 1A2	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 1A2	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 1A2	Homo sapiens (human)
enzyme binding	Cytochrome P450 1A2	Homo sapiens (human)
heme binding	Cytochrome P450 1A2	Homo sapiens (human)
demethylase activity	Cytochrome P450 1A2	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 1A2	Homo sapiens (human)
aromatase activity	Cytochrome P450 1A2	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 1A2	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 1A2	Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activity	Cytochrome P450 1A2	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
steroid binding	Cytochrome P450 3A4	Homo sapiens (human)
iron ion binding	Cytochrome P450 3A4	Homo sapiens (human)
protein binding	Cytochrome P450 3A4	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid 4-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxygen binding	Cytochrome P450 3A4	Homo sapiens (human)
enzyme binding	Cytochrome P450 3A4	Homo sapiens (human)
heme binding	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D3 25-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
quinine 3-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
testosterone 6-beta-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
aromatase activity	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D 24-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2D6	Homo sapiens (human)
iron ion binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2D6	Homo sapiens (human)
heme binding	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 2C9	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C9	Homo sapiens (human)
heme binding	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C9	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
endoplasmic reticulum membrane	Cytochrome P450 1A2	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 1A2	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 1A2	Homo sapiens (human)
cytoplasm	Cytochrome P450 3A4	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 3A4	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 3A4	Homo sapiens (human)
mitochondrion	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2D6	Homo sapiens (human)
cytoplasm	Cytochrome P450 2D6	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2C9	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (217)

Assay ID	Title	Year	Journal	Article
AID745401	Antibacterial activity against Streptococcus pneumoniae SR26207 clinical isolate assessed as growth inhibition by CLSI broth microdilution method	2013	European journal of medicinal chemistry, May, Volume: 63	Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.
AID209934	Inhibitory activity against Streptococcus pyogenes	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	New directions in antibacterial research.
AID208011	The compound was evaluated for its anti-bacterial activity against Streptococcus pneumoniae UC 9912	1998	Journal of medicinal chemistry, Dec-17, Volume: 41, Issue:26	Nitrogen-carbon-linked (azolylphenyl)oxazolidinones with potent antibacterial activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis.
AID206787	Inhibitory activity against MSSA	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	New directions in antibacterial research.
AID383564	Antibacterial activity against Staphylococcus aureus ATCC 29213 by broth microdilution technique	2008	European journal of medicinal chemistry, Apr, Volume: 43, Issue:4	Synthesis and in vitro antibacterial activities of novel oxazolidinones.
AID206088	In vitro anti-streptococcal activity against Streptococci species (viridans) [25]* expressed as geometric mean	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID125242	The compound was evaluated for its anti-bacterial activity against Moraxella catarrhalis UC 30610	1998	Journal of medicinal chemistry, Dec-17, Volume: 41, Issue:26	Nitrogen-carbon-linked (azolylphenyl)oxazolidinones with potent antibacterial activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis.
AID65385	Inhibitory activity against Enterococcus faecalis UC9217	2000	Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5	Substituent effects on the antibacterial activity of nitrogen-carbon-linked (azolylphenyl)oxazolidinones with expanded activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis.
AID383565	Antibacterial activity against Staphylococcus aureus ATCC 9144 by broth microdilution technique	2008	European journal of medicinal chemistry, Apr, Volume: 43, Issue:4	Synthesis and in vitro antibacterial activities of novel oxazolidinones.
AID125104	Inhibitory activity against Moraxella catarrhalis	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	New directions in antibacterial research.
AID1369124	Antibacterial activity against Acinetobacter baumannii ATCC 17978 after 18 hrs by broth microdilution method	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	A Synthetic Dual Drug Sideromycin Induces Gram-Negative Bacteria To Commit Suicide with a Gram-Positive Antibiotic.
AID745400	Antibacterial activity against Haemophilus influenzae SR27914 clinical isolate assessed as growth inhibition by CLSI broth microdilution method	2013	European journal of medicinal chemistry, May, Volume: 63	Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.
AID319146	Solubility in phosphate buffer at pH 7	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections.
AID67579	Minimum inhibitory concentration against Enterococcus faecalis UC9217	1998	Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19	Piperazinyl oxazolidinone antibacterial agents containing a pyridine, diazene, or triazene heteroaromatic ring.
AID244815	Minimum inhibitory concentration against Staphylococcus aureus A15090	2005	Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11	Synthesis and antibacterial activity of dihydro-1,2-oxazine and 2-pyrazoline oxazolidinones: novel analogs of linezolid.
AID50998	In vitro antibacterial activity against Clostridium perfringens strain ATCC 13124	1996	Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3	Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections.
AID134123	Protective dose of subcutaneously administered compound against intraperitoneally-induced septicaemia model (Staphylococcus aureus HT18) in murine	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID133300	Minimum inhibitory concentration of the subcutaneously administered compound evaluated against Staphylococcus aureus HT-18 strain in mice	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID201444	Inhibitory activity against Methicillin-resistant Staphylococcus epidermidis UC12084	2000	Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5	Substituent effects on the antibacterial activity of nitrogen-carbon-linked (azolylphenyl)oxazolidinones with expanded activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis.
AID207511	Minimum inhibitory concentration against Staphylococcus aureus UC9213	1998	Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19	Piperazinyl oxazolidinone antibacterial agents containing a pyridine, diazene, or triazene heteroaromatic ring.
AID262232	Antibacterial activity against Staphylococcus aureus ATCC 29213	2006	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6	Novel 4-N-substituted aryl pent-2-ene-1,4-dione derivatives of piperazinyloxazolidinones as antibacterials.
AID383556	Antibacterial activity against Bacillus cereus ATCC 11778 by broth microdilution technique	2008	European journal of medicinal chemistry, Apr, Volume: 43, Issue:4	Synthesis and in vitro antibacterial activities of novel oxazolidinones.
AID745402	Antibacterial activity against Moraxella catarrhalis SR26840 clinical isolate assessed as growth inhibition by CLSI broth microdilution method	2013	European journal of medicinal chemistry, May, Volume: 63	Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.
AID197767	Compound was evaluated for metabolic stability via In vitro Rat 5E6 cell at 50 uM concentration	2003	Journal of medicinal chemistry, Jan-16, Volume: 46, Issue:2	Identification of phenylisoxazolines as novel and viable antibacterial agents active against Gram-positive pathogens.
AID205680	Minimum inhibitory concentration against Staphylococcus aureus MTCC 96; Not determined	2004	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12	Oxazolidinone: search for highly potent antibacterial.
AID1553369	Inhibition of protein synthesis in mitochondria (unknown origin) assessed as [35S]methionine incorporation incubated for 15 to 120 mins by paper disk assay	2019	Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18	Incorporation of a chiral gem-disubstituted nitrogen heterocycle yields an oxazolidinone antibiotic with reduced mitochondrial toxicity.
AID308916	Antibacterial activity against Staphylococcus aureus ATCC 33591 by broth microdilution method	2007	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18	Synthesis and in vitro antibacterial activity of novel methylamino piperidinyl oxazolidinones.
AID134119	Protective dose of subcutaneously administered compound against intraperitoneally-induced septicaemia model (Staphylococcus agalactiae B1HT3 strain) in murine	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID745382	Antibacterial activity against methicillin-resistant Staphylococcus aureus SR3637 infected in JCL/ICR mouse systemic infection model assessed as mortality administered as iv measured over 7 days	2013	European journal of medicinal chemistry, May, Volume: 63	Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.
AID201408	Inhibitory activity against Methicillin-resistant Staphylococcus aureus UC6685	2000	Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5	Substituent effects on the antibacterial activity of nitrogen-carbon-linked (azolylphenyl)oxazolidinones with expanded activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis.
AID383566	Antibacterial activity against Staphylococcus aureus ATCC 14154 by broth microdilution technique	2008	European journal of medicinal chemistry, Apr, Volume: 43, Issue:4	Synthesis and in vitro antibacterial activities of novel oxazolidinones.
AID206127	In vitro antibacterial activity against ciprofloxacin-resistant Staphylococcus aureus (CRSA) C6043.	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and in vitro activity of new oxazolidinone antibacterial agents having substituted isoxazoles.
AID226024	Protective dose of subcutaneously administered compound against intraperitoneally-induced septicaemia model (vancomycin resistant Enterococci faecium D3AP9 strain ) in murine	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID112683	In vivo antibacterial activity against Enterococcus faecium strain UC 15090 administered perorally in mice	1996	Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3	Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections.
AID206090	Minimum inhibitory concentration evaluated against Streptococci species (viridans) [25]*	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID223270	Dose required to cure 50% of Staphylococcus aureus infected mice in the presence of vancomycin when administered orally; value ranges from 2.5-6.4	2000	Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5	Substituent effects on the antibacterial activity of nitrogen-carbon-linked (azolylphenyl)oxazolidinones with expanded activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis.
AID745383	Antibacterial activity against methicillin-resistant Staphylococcus aureus SR3637 assessed as growth inhibition by CLSI broth microdilution method	2013	European journal of medicinal chemistry, May, Volume: 63	Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.
AID128015	Compound was tested against Staphylococcus aureus UC9213 after po administration in mouse	1998	Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19	Piperazinyl oxazolidinone antibacterial agents containing a pyridine, diazene, or triazene heteroaromatic ring.
AID262231	Antibacterial activity against Staphylococcus aureus ATCC 14154	2006	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6	Novel 4-N-substituted aryl pent-2-ene-1,4-dione derivatives of piperazinyloxazolidinones as antibacterials.
AID27799	Volume distribution in Male Sprague-Dawley Rat (25 mg/kg po); NC denotes not calculated	2003	Journal of medicinal chemistry, Jan-16, Volume: 46, Issue:2	Identification of phenylisoxazolines as novel and viable antibacterial agents active against Gram-positive pathogens.
AID266689	Antibacterial activity against Staphylococcus aureus ATCC 25923	2006	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 16, Issue:14	3D QSAR studies of N-4-arylacryloylpiperazin-1-yl-phenyl-oxazolidinones: a novel class of antibacterial agents.
AID383569	Antibacterial activity against linezolid-resistant Staphylococcus aureus NRS 120 with G 2576T mutation by broth microdilution technique	2008	European journal of medicinal chemistry, Apr, Volume: 43, Issue:4	Synthesis and in vitro antibacterial activities of novel oxazolidinones.
AID206841	Minimum inhibitory concentration evaluated against Staphylococcus species resistant to oxacillin and ofloxacin [47]*	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID94375	In vitro antibacterial activity against Klebsiella pneumoniae strain UC 12081	1996	Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3	Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections.
AID29427	Oral bioavailability in rat (Sprague-Dawley) (male) (dose 10 mg/kg i.v.)	2003	Journal of medicinal chemistry, Jan-16, Volume: 46, Issue:2	Identification of phenylisoxazolines as novel and viable antibacterial agents active against Gram-positive pathogens.
AID308921	Antibacterial activity against Staphylococcus aureus ATCC 25923 by broth microdilution method	2007	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18	Synthesis and in vitro antibacterial activity of novel methylamino piperidinyl oxazolidinones.
AID206786	Inhibitory activity against MRSA	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	New directions in antibacterial research.
AID223279	Dose required to cure 50% of Staphylococcus aureus infected mice when administered orally; value ranges from 1.4-3.8	2000	Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5	Substituent effects on the antibacterial activity of nitrogen-carbon-linked (azolylphenyl)oxazolidinones with expanded activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis.
AID66098	Inhibitory activity against Enterococcus faecium	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	New directions in antibacterial research.
AID67894	The compound was evaluated for its anti-bacterial activity against Enterococcus faecalis UC 9217	1998	Journal of medicinal chemistry, Dec-17, Volume: 41, Issue:26	Nitrogen-carbon-linked (azolylphenyl)oxazolidinones with potent antibacterial activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis.
AID133297	Minimum inhibitory concentration of the subcutaneously administered compound evaluated against Staphylococcus aureus GR56 strain resistant to oxacillin in mice	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID79584	Inhibitory activity against Haemophilus influenzae UC30063	2000	Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5	Substituent effects on the antibacterial activity of nitrogen-carbon-linked (azolylphenyl)oxazolidinones with expanded activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis.
AID245167	Minimum inhibitory concentration against homogeneously methicillin-resistant Staphylococcus aureus A27223	2005	Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11	Synthesis and antibacterial activity of dihydro-1,2-oxazine and 2-pyrazoline oxazolidinones: novel analogs of linezolid.
AID40483	Minimum inhibitory concentration against Bacillus pumilus MTCC 1607	2004	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12	Oxazolidinone: search for highly potent antibacterial.
AID206281	In vitro antibacterial activity against Staphylococcus aureus (S. a.) ATCC 29213.	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and in vitro activity of new oxazolidinone antibacterial agents having substituted isoxazoles.
AID66561	Minimum inhibitory concentration evaluated against enterococci species susceptible to vancomycin [26]*	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID226027	Protective dose of subcutaneously administered compound against intraperitoneally-induced septicaemia model (vancomycin resistant Enterococci faecium D3HT12 strain ) in murine	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID245196	Minimum inhibitory concentration against heterogeneously methicillin-resistant Staphylococcus aureus A27218	2005	Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11	Synthesis and antibacterial activity of dihydro-1,2-oxazine and 2-pyrazoline oxazolidinones: novel analogs of linezolid.
AID91253	Compound was evaluated for metabolic stability via In vitro Human 5E6 cell at 25 uM concentration; ND denotes not determined	2003	Journal of medicinal chemistry, Jan-16, Volume: 46, Issue:2	Identification of phenylisoxazolines as novel and viable antibacterial agents active against Gram-positive pathogens.
AID206089	In vitro anti-streptococcal activity against Streptococci species [38]* expressed as geometric mean	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID209767	Minimum inhibitory concentration against Streptococcus pyogenes MTCC 442	2004	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12	Oxazolidinone: search for highly potent antibacterial.
AID206727	In vitro antibacterial activity against the methicillin-resistant Staphylococcus aureus 88	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	3D QSAR studies on new oxazolidinone antibacterial agents by comparative molecular field analysis.
AID68242	In vitro antibacterial activity against Enterococcus faecium C6301 (E.f.2).	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and in vitro activity of new oxazolidinone antibacterial agents having substituted isoxazoles.
AID262228	Antibacterial activity against Enterococcus faecalis ATCC 35550	2006	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6	Novel 4-N-substituted aryl pent-2-ene-1,4-dione derivatives of piperazinyloxazolidinones as antibacterials.
AID133419	Minimum inhibitory concentration of the subcutaneously administered compound evaluated against vancomycin resistant Enterococci faecium D3HM4 strain in mice	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID205897	Minimum inhibitory concentration against Staphylococcus epidermidis MTCC 155	2004	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12	Oxazolidinone: search for highly potent antibacterial.
AID68385	In vitro antibacterial activity against Enterococcus faecium strain UC12712	1996	Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3	Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections.
AID244814	Minimum inhibitory concentration against Enterococcus faecalis A20688	2005	Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11	Synthesis and antibacterial activity of dihydro-1,2-oxazine and 2-pyrazoline oxazolidinones: novel analogs of linezolid.
AID206234	Minimum inhibitory concentration against Staphylococcus epidermis UC12084	1998	Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19	Piperazinyl oxazolidinone antibacterial agents containing a pyridine, diazene, or triazene heteroaromatic ring.
AID308915	Antibacterial activity against Enterococcus faecalis ATCC 14506 by broth microdilution method	2007	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18	Synthesis and in vitro antibacterial activity of novel methylamino piperidinyl oxazolidinones.
AID28208	Tmax value in Male Sprague-Dawley Rat at dose 10 (mg/kg iv) [tmax (h)]; ND denotes not reported	2003	Journal of medicinal chemistry, Jan-16, Volume: 46, Issue:2	Identification of phenylisoxazolines as novel and viable antibacterial agents active against Gram-positive pathogens.
AID134121	Protective dose of subcutaneously administered compound against intraperitoneally-induced septicaemia model (Staphylococcus aureus GR56 strain resistant to oxacillin) in murine	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID319151	Toxicity in rat at 25 mg/kg for 30 days	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections.
AID93890	Minimum inhibitory concentration against Klebsiella pneumoniae ATCC 10031	2004	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12	Oxazolidinone: search for highly potent antibacterial.
AID383561	Antibacterial activity against Enterococcus faecalis ATCC 14506 by broth microdilution technique	2008	European journal of medicinal chemistry, Apr, Volume: 43, Issue:4	Synthesis and in vitro antibacterial activities of novel oxazolidinones.
AID383563	Antibacterial activity against vancomycin-resistant Enterococcus faecium ATCC 700221 by broth microdilution technique	2008	European journal of medicinal chemistry, Apr, Volume: 43, Issue:4	Synthesis and in vitro antibacterial activities of novel oxazolidinones.
AID226022	Protective dose of subcutaneously administered compound against intraperitoneally-induced septicaemia model (Enterococci faecium D3HT7 strain ) in murine	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID209475	In vitro antibacterial activity against Streptococcus pyogenes strain UC 152	1996	Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3	Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections.
AID206839	Minimum inhibitory concentration evaluated against Staphylococcus species resistant to ofloxacin [59]*	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID1369125	Antibacterial activity against Acinetobacter baumannii ATCC 17978 transfected with pNT255 after 18 hrs by broth microdilution method	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	A Synthetic Dual Drug Sideromycin Induces Gram-Negative Bacteria To Commit Suicide with a Gram-Positive Antibiotic.
AID383567	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 700699 by broth microdilution technique	2008	European journal of medicinal chemistry, Apr, Volume: 43, Issue:4	Synthesis and in vitro antibacterial activities of novel oxazolidinones.
AID226021	Protective dose of subcutaneously administered compound against intraperitoneally-induced septicaemia model (Enterococci faecalis D2HT6 strain) in murine	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID308922	Antibacterial activity against linezolid-resistant Staphylococcus aureus NRS 119 by broth microdilution method	2007	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18	Synthesis and in vitro antibacterial activity of novel methylamino piperidinyl oxazolidinones.
AID83650	Inhibitory activity against Haemophilus influenzae	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	New directions in antibacterial research.
AID66405	In vitro anti-enterococcal activity against enterococci species resistant to vancomycin [65]* expressed as geometric mean	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID319152	Toxicity in dog at 25 mg/kg for 30 days	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections.
AID112686	In vivo antibacterial activity against Staphylococcus aures strain UC 9213 administered subcutaneously in mice	1996	Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3	Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections.
AID68244	In vitro antibacterial activity against vancomycin-resistant Enterococcus faecium C6487 (VRE).	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and in vitro activity of new oxazolidinone antibacterial agents having substituted isoxazoles.
AID1471363	Inhibition of coupled transcription-translation in Escherichia coli UC6782 30S ribosome subunit using ortho-nitrophenyl-beta-galactoside as substrate after 30 mins by spectrophotometry	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Causes and Significance of Increased Compound Potency in Cellular or Physiological Contexts.
AID308914	Antibacterial activity against Enterococcus faecalis ATCC 29212 by broth microdilution method	2007	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18	Synthesis and in vitro antibacterial activity of novel methylamino piperidinyl oxazolidinones.
AID206833	In vitro anti-staphylococcal activity against Staphylococcus species resistant to oxacillin [66]* expressed as geometric mean	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID308913	Antibacterial activity against Staphylococcus epidermidis ATCC 12228 by broth microdilution method	2007	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18	Synthesis and in vitro antibacterial activity of novel methylamino piperidinyl oxazolidinones.
AID133294	Minimum inhibitory concentration of the subcutaneously administered compound evaluated against Staphylococcus agalactiae B1HT3 strain in mice	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID206228	In vitro antibacterial activity against Staphylococcus epidermis strain UC 30031	1996	Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3	Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections.
AID206236	In vitro antibacterial activity against Staphylococcus aures strain ATCC 29213	1996	Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3	Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections.
AID745403	Antibacterial activity against Enterococcus faecium SR7940 clinical isolate assessed as growth inhibition by CLSI broth microdilution method	2013	European journal of medicinal chemistry, May, Volume: 63	Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.
AID210379	In vitro antibacterial activity against Streptococcus pneumoniae strain UC 9912	1996	Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3	Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections.
AID745405	Antibacterial activity against linezolid-resistant Staphylococcus aureus NRS271 assessed as growth inhibition by CLSI broth microdilution method	2013	European journal of medicinal chemistry, May, Volume: 63	Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.
AID745374	Inhibition of MAO-A in rat forebrain using [14C]5-HT as substrate at 30 uM incubated for 20 mins prior to substrate addition measured after 5 mins by liquid scintillation counting analysis relative to control	2013	European journal of medicinal chemistry, May, Volume: 63	Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.
AID28087	Cmax value in Male Sprague-Dawley Rat at dose 25 (mg/kg po)	2003	Journal of medicinal chemistry, Jan-16, Volume: 46, Issue:2	Identification of phenylisoxazolines as novel and viable antibacterial agents active against Gram-positive pathogens.
AID383558	Antibacterial activity against Staphylococcus epidermidis ATCC 155 by broth microdilution technique	2008	European journal of medicinal chemistry, Apr, Volume: 43, Issue:4	Synthesis and in vitro antibacterial activities of novel oxazolidinones.
AID28199	Plasma clearance in Male Sprague-Dawley Rat (25 mg/kg po); ND denotes not reported	2003	Journal of medicinal chemistry, Jan-16, Volume: 46, Issue:2	Identification of phenylisoxazolines as novel and viable antibacterial agents active against Gram-positive pathogens.
AID262234	Antibacterial activity against linezolid-resistant Staphylococcus aureus NRS 119	2006	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6	Novel 4-N-substituted aryl pent-2-ene-1,4-dione derivatives of piperazinyloxazolidinones as antibacterials.
AID206237	In vitro antibacterial activity against Staphylococcus aures strain UC 9213	1996	Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3	Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections.
AID145139	In vitro antibacterial activity against Mycobacterium tuberculosis strain H37Rv	1996	Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3	Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections.
AID745406	Antibacterial activity against Staphylococcus aureus Smith assessed as growth inhibition by CLSI broth microdilution method	2013	European journal of medicinal chemistry, May, Volume: 63	Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.
AID262226	Antibacterial activity against Bacillus pumilus ATCC 14348	2006	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6	Novel 4-N-substituted aryl pent-2-ene-1,4-dione derivatives of piperazinyloxazolidinones as antibacterials.
AID112685	In vivo antibacterial activity against Staphylococcus aures strain UC 9213 administered perorally in mice	1996	Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3	Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections.
AID1369126	Antibacterial activity against Acinetobacter baumannii ATCC 17978 transfected with pNT255:ADC-1 after 18 hrs by broth microdilution method	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	A Synthetic Dual Drug Sideromycin Induces Gram-Negative Bacteria To Commit Suicide with a Gram-Positive Antibiotic.
AID67400	In vitro antibacterial activity against Enterococcus faecalis strain ATCC 29212	1996	Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3	Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections.
AID67752	Minimum inhibitory concentration against Enterococcus faecalis ATCC 14506	2004	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12	Oxazolidinone: search for highly potent antibacterial.
AID133421	Minimum inhibitory concentration of the subcutaneously administered compound evaluated against vancomycin resistant Enterococci faecium D3HT12 strain in mice	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID244819	Minimum inhibitory concentration against Streptococcus pneumoniae A9585	2005	Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11	Synthesis and antibacterial activity of dihydro-1,2-oxazine and 2-pyrazoline oxazolidinones: novel analogs of linezolid.
AID308918	Antibacterial activity against Staphylococcus aureus ATCC 33592 by broth microdilution method	2007	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18	Synthesis and in vitro antibacterial activity of novel methylamino piperidinyl oxazolidinones.
AID208630	Inhibitory activity against Streptococcus pneumoniae	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	New directions in antibacterial research.
AID133306	Minimum inhibitory concentration of the subcutaneously administered compound evaluated against vancomycin resistant Enterococci faecium D3HM3 strain in mice	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID206238	In vitro antibacterial activity against Staphylococcus aures strain UC12673	1996	Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3	Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections.
AID112681	In vivo antibacterial activity against Enterococcus faecalis strain UC 12379 administered perorally in mice	1996	Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3	Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections.
AID262230	Antibacterial activity against Staphylococcus aureus ATCC 9144	2006	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6	Novel 4-N-substituted aryl pent-2-ene-1,4-dione derivatives of piperazinyloxazolidinones as antibacterials.
AID206470	The compound was evaluated for its anti-bacterial activity against methicillin susceptible Staphylococcus aureus	1998	Journal of medicinal chemistry, Dec-17, Volume: 41, Issue:26	Nitrogen-carbon-linked (azolylphenyl)oxazolidinones with potent antibacterial activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis.
AID206840	Minimum inhibitory concentration evaluated against Staphylococcus species resistant to oxacillin [66]*	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID206451	In vitro antibacterial activity against methicillin-susceptible Staphylococcus aureus (MSSA) C2214.	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and in vitro activity of new oxazolidinone antibacterial agents having substituted isoxazoles.
AID23886	Plasma clearance in Male Sprague-Dawley Rat (10 mg/kg iv)	2003	Journal of medicinal chemistry, Jan-16, Volume: 46, Issue:2	Identification of phenylisoxazolines as novel and viable antibacterial agents active against Gram-positive pathogens.
AID206055	Inhibitory activity against methicillin-resistant Staphylococcus epidermidis (MRSE)	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	New directions in antibacterial research.
AID262237	Antibacterial activity against Streptococcus pyogenes ATCC 14289	2006	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6	Novel 4-N-substituted aryl pent-2-ene-1,4-dione derivatives of piperazinyloxazolidinones as antibacterials.
AID206834	In vitro anti-staphylococcal activity against Staphylococcus species resistant to oxacillin and ofloxacin[47]* expressed as geometric mean	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID16465	Calculated partition coefficient (clogP)	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	3D QSAR studies on new oxazolidinone antibacterial agents by comparative molecular field analysis.
AID66407	In vitro anti-enterococcal activity against enterococci species susceptible to vancomycin [26]* expressed as geometric mean	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID83641	The compound was evaluated for its anti-bacterial activity against Haemophilus influenzae UC 30063	1998	Journal of medicinal chemistry, Dec-17, Volume: 41, Issue:26	Nitrogen-carbon-linked (azolylphenyl)oxazolidinones with potent antibacterial activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis.
AID383562	Antibacterial activity against multidrug-resistant Enterococcus faecalis ATCC 700802 by broth microdilution technique	2008	European journal of medicinal chemistry, Apr, Volume: 43, Issue:4	Synthesis and in vitro antibacterial activities of novel oxazolidinones.
AID30967	Harmonic mean apparent terminal disposition half-life [t1/2beta (h)] in Male Sprague-Dawley Rat at dose 10 (mg/kg iv)	2003	Journal of medicinal chemistry, Jan-16, Volume: 46, Issue:2	Identification of phenylisoxazolines as novel and viable antibacterial agents active against Gram-positive pathogens.
AID226025	Protective dose of subcutaneously administered compound against intraperitoneally-induced septicaemia model (vancomycin resistant Enterococci faecium D3HM3 strain ) in murine	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID1471364	Binding affinity to Escherichia coli MRE600 50S ribosome after 10 mins by radioligand binding assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Causes and Significance of Increased Compound Potency in Cellular or Physiological Contexts.
AID226023	Protective dose of subcutaneously administered compound against intraperitoneally-induced septicaemia model (Staphylococcus pyogenes A1UC1 strain) in murine	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID383555	Antibacterial activity against Bacillus pumilus ATCC 14884 by broth microdilution technique	2008	European journal of medicinal chemistry, Apr, Volume: 43, Issue:4	Synthesis and in vitro antibacterial activities of novel oxazolidinones.
AID30153	Volume distribution in Male Sprague-Dawley Rat (10 mg/kg iv)	2003	Journal of medicinal chemistry, Jan-16, Volume: 46, Issue:2	Identification of phenylisoxazolines as novel and viable antibacterial agents active against Gram-positive pathogens.
AID28179	Harmonic mean apparent terminal disposition half-life [t1/2beta (h)] in Male Sprague-Dawley Rat at dose 25 (mg/kg po); ND denotes not reported	2003	Journal of medicinal chemistry, Jan-16, Volume: 46, Issue:2	Identification of phenylisoxazolines as novel and viable antibacterial agents active against Gram-positive pathogens.
AID41285	Inhibitory activity against Bacteroides fragilis	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	New directions in antibacterial research.
AID206450	In vitro antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) C6068.	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and in vitro activity of new oxazolidinone antibacterial agents having substituted isoxazoles.
AID383559	Antibacterial activity against Enterococcus faecalis ATCC 35550 by broth microdilution technique	2008	European journal of medicinal chemistry, Apr, Volume: 43, Issue:4	Synthesis and in vitro antibacterial activities of novel oxazolidinones.
AID41262	In vitro antibacterial activity against Bacteroides fragilis strain ATCC 25285	1996	Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3	Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections.
AID745373	Inhibition of MAO-B in rat forebrain using [14C]PEA as substrate at 30 uM incubated for 20 mins prior to substrate addition measured after 10 mins by liquid scintillation counting analysis relative to control	2013	European journal of medicinal chemistry, May, Volume: 63	Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.
AID262236	Antibacterial activity against vancomycin-resistant Enterococcus faecalis ATCC 700802	2006	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6	Novel 4-N-substituted aryl pent-2-ene-1,4-dione derivatives of piperazinyloxazolidinones as antibacterials.
AID202107	Inhibitory activity against Streptococcus pneumoniae UC9912	2000	Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5	Substituent effects on the antibacterial activity of nitrogen-carbon-linked (azolylphenyl)oxazolidinones with expanded activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis.
AID133303	Minimum inhibitory concentration of the subcutaneously administered compound evaluated against Staphylococcus pyogenes A1UC1 strain in mice	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID308912	Antibacterial activity against Bacillus subtilis ATCC 6633 by broth microdilution method	2007	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18	Synthesis and in vitro antibacterial activity of novel methylamino piperidinyl oxazolidinones.
AID66406	In vitro anti-enterococcal activity against enterococci species resistant to vancomycin and teicoplanin [17]* expressed as geometric mean	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID71095	In vitro antibacterial activity against Escherichia coli strain ATCC 25922	1996	Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3	Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections.
AID262235	Antibacterial activity against Enterococcus faecalis ATCC 14506	2006	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6	Novel 4-N-substituted aryl pent-2-ene-1,4-dione derivatives of piperazinyloxazolidinones as antibacterials.
AID165190	In vitro antibacterial activity against Pseudomonas aeruginosa strain ATCC 27853	1996	Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3	Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections.
AID29429	Oral bioavailability in rat (Sprague-Dawley) (male) (dose 25 mg/kg p.o.)	2003	Journal of medicinal chemistry, Jan-16, Volume: 46, Issue:2	Identification of phenylisoxazolines as novel and viable antibacterial agents active against Gram-positive pathogens.
AID206993	The compound was evaluated for its anti-bacterial activity against methicillin resistant Staphylococcus epidermidis	1998	Journal of medicinal chemistry, Dec-17, Volume: 41, Issue:26	Nitrogen-carbon-linked (azolylphenyl)oxazolidinones with potent antibacterial activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis.
AID745378	Inhibition of human CYP2C9 assessed as tolbutamide hydroxylation after 20 mins by LC/MS/MS analysis	2013	European journal of medicinal chemistry, May, Volume: 63	Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.
AID205559	Minimum inhibitory concentration against Staphylococcus aureus ATCC 14154	2004	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12	Oxazolidinone: search for highly potent antibacterial.
AID161942	Minimum inhibitory concentration evaluated against pneumococci resistant to penicillin [29]*	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID206613	In vitro antibacterial activity against the methicillin-resistant Staphylococcus aureus 88	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	3D QSAR studies on new oxazolidinone antibacterial agents by comparative molecular field analysis.
AID206830	In vitro anti-staphylococcal activity against Staphylococcus species [91]* expressed as geometric mean	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID206223	In vitro antibacterial activity against Staphylococcus epidermis (S.e.2) C2235.	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and in vitro activity of new oxazolidinone antibacterial agents having substituted isoxazoles.
AID745377	Inhibition of human CYP1A2 assessed as ethoxyresorufin O-deethylation after 20 mins by fluorescence plate reader analysis	2013	European journal of medicinal chemistry, May, Volume: 63	Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.
AID308926	Antibacterial activity against Staphylococcus epidermidis ATCC 155 by broth microdilution method	2007	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18	Synthesis and in vitro antibacterial activity of novel methylamino piperidinyl oxazolidinones.
AID1553368	Antibacterial activity against Staphylococcus aureus JC9213 by CLSI based broth dilution assay	2019	Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18	Incorporation of a chiral gem-disubstituted nitrogen heterocycle yields an oxazolidinone antibiotic with reduced mitochondrial toxicity.
AID161929	In vitro anti-streptococcal activity against pneumococci resistant to penicillin [29]* expressed as geometric mean	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID133304	Minimum inhibitory concentration of the subcutaneously administered compound evaluated against vancomycin resistant Enterococci faecium D3AP9 strain in mice	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID308917	Antibacterial activity against Staphylococcus aureus ATCC 29213 by broth microdilution method	2007	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18	Synthesis and in vitro antibacterial activity of novel methylamino piperidinyl oxazolidinones.
AID209464	In vitro antibacterial activity against Streptococcus pyogenes C6003 (S.p.2).	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and in vitro activity of new oxazolidinone antibacterial agents having substituted isoxazoles.
AID66560	Minimum inhibitory concentration evaluated against enterococci species resistant to vancomycin and teicoplanin [17]*	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID103859	Inhibitory activity against Moraxella catarrhalis UC30610	2000	Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5	Substituent effects on the antibacterial activity of nitrogen-carbon-linked (azolylphenyl)oxazolidinones with expanded activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis.
AID205561	Minimum inhibitory concentration against Staphylococcus aureus ATCC 29213	2004	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12	Oxazolidinone: search for highly potent antibacterial.
AID319150	Oral bioavailability in dog at 25 mg/kg	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections.
AID40326	Minimum inhibitory concentration against Bacillus cereus MTCC 430	2004	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12	Oxazolidinone: search for highly potent antibacterial.
AID308920	Antibacterial activity against vancomycin-resistant Enterococcus faecium ATCC 700221 by broth microdilution method	2007	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18	Synthesis and in vitro antibacterial activity of novel methylamino piperidinyl oxazolidinones.
AID206832	In vitro anti-staphylococcal activity against Staphylococcus species resistant to ofloxacin [59]* expressed as geometric mean	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID132799	compound was tested against Staphylococcus aureus UC9213 the vancomycin administered (sc) in mouse positive control expressed as ED50 values.	1998	Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19	Piperazinyl oxazolidinone antibacterial agents containing a pyridine, diazene, or triazene heteroaromatic ring.
AID745407	Antibacterial activity against Staphylococcus aureus SR20549 clinical isolate assessed as growth inhibition by CLSI broth microdilution method	2013	European journal of medicinal chemistry, May, Volume: 63	Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.
AID206056	Inhibitory activity against methicillin-sensitive Staphylococcus epidermidis (MSSE)	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	New directions in antibacterial research.
AID262233	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 700699	2006	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6	Novel 4-N-substituted aryl pent-2-ene-1,4-dione derivatives of piperazinyloxazolidinones as antibacterials.
AID67243	In vitro antibacterial activity against Enterococcus faecalis C6291 (E.f.1).	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and in vitro activity of new oxazolidinone antibacterial agents having substituted isoxazoles.
AID226026	Protective dose of subcutaneously administered compound against intraperitoneally-induced septicaemia model (vancomycin resistant Enterococci faecium D3HM4 strain ) in murine	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID54143	Inhibitory activity against Corynebacterium	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	New directions in antibacterial research.
AID208149	Minimum inhibitory concentration Streptococcus pneumoniae UC9912	1998	Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19	Piperazinyl oxazolidinone antibacterial agents containing a pyridine, diazene, or triazene heteroaromatic ring.
AID308919	Antibacterial activity against multidrug resistant Enterococcus faecalis ATCC 700802 by broth microdilution method	2007	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18	Synthesis and in vitro antibacterial activity of novel methylamino piperidinyl oxazolidinones.
AID205560	Minimum inhibitory concentration against Staphylococcus aureus ATCC 25923	2004	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12	Oxazolidinone: search for highly potent antibacterial.
AID206469	The compound was evaluated for its anti-bacterial activity against methicillin resistant Staphylococcus aureus	1998	Journal of medicinal chemistry, Dec-17, Volume: 41, Issue:26	Nitrogen-carbon-linked (azolylphenyl)oxazolidinones with potent antibacterial activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis.
AID745404	Antibacterial activity against Enterococcus faecalis SR1004 clinical isolate assessed as growth inhibition by CLSI broth microdilution method	2013	European journal of medicinal chemistry, May, Volume: 63	Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.
AID308924	Antibacterial activity against methicillin-resistant Streptococcus pyogenes ATCC 14289 by broth microdilution method	2007	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18	Synthesis and in vitro antibacterial activity of novel methylamino piperidinyl oxazolidinones.
AID262229	Antibacterial activity against Staphylococcus aureus ATCC 25923	2006	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6	Novel 4-N-substituted aryl pent-2-ene-1,4-dione derivatives of piperazinyloxazolidinones as antibacterials.
AID383568	Antibacterial activity against linezolid-resistant Staphylococcus aureus NRS 119 with G 2576T mutation by broth microdilution technique	2008	European journal of medicinal chemistry, Apr, Volume: 43, Issue:4	Synthesis and in vitro antibacterial activities of novel oxazolidinones.
AID383570	Antibacterial activity against multidrug-resistant Streptococcus pneumoniae ATCC 700904 by broth microdilution technique	2008	European journal of medicinal chemistry, Apr, Volume: 43, Issue:4	Synthesis and in vitro antibacterial activities of novel oxazolidinones.
AID206222	In vitro antibacterial activity against Staphylococcus epidermis (S.e.1) ATCC 1228.	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and in vitro activity of new oxazolidinone antibacterial agents having substituted isoxazoles.
AID133291	Minimum inhibitory concentration of the subcutaneously administered compound evaluated against Enterococci faecium D3HT7 strain in mice	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID29723	Tmax value in Male Sprague-Dawley Rat at dose 25 (mg/kg po) [tmax (h)]	2003	Journal of medicinal chemistry, Jan-16, Volume: 46, Issue:2	Identification of phenylisoxazolines as novel and viable antibacterial agents active against Gram-positive pathogens.
AID319159	Plasma concentration in human at 2000 mg, qid after 2 hrs	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections.
AID745375	Inhibition of human CYP3A4 assessed as terfenadine hydroxylation after 20 mins by LC/MS/MS analysis	2013	European journal of medicinal chemistry, May, Volume: 63	Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.
AID262227	Antibacterial activity against Staphylococcus epidermidis ATCC 155	2006	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6	Novel 4-N-substituted aryl pent-2-ene-1,4-dione derivatives of piperazinyloxazolidinones as antibacterials.
AID207510	Minimum inhibitory concentration against Staphylococcus aureus UC6685	1998	Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19	Piperazinyl oxazolidinone antibacterial agents containing a pyridine, diazene, or triazene heteroaromatic ring.
AID209463	In vitro antibacterial activity against Streptococcus pyogenes ATCC 8668 (S.p.1).	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	Synthesis and in vitro activity of new oxazolidinone antibacterial agents having substituted isoxazoles.
AID383557	Antibacterial activity against Streptococcus pyogenes ATCC 14289 by broth microdilution technique	2008	European journal of medicinal chemistry, Apr, Volume: 43, Issue:4	Synthesis and in vitro antibacterial activities of novel oxazolidinones.
AID308925	Antibacterial activity against multidrug-resistant Streptococcus pneumoniae ATCC 700904 by broth microdilution method	2007	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18	Synthesis and in vitro antibacterial activity of novel methylamino piperidinyl oxazolidinones.
AID308923	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 700699 by broth microdilution method	2007	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18	Synthesis and in vitro antibacterial activity of novel methylamino piperidinyl oxazolidinones.
AID206838	Minimum inhibitory concentration evaluated against Staphylococcus species [91]*	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID201410	Inhibitory activity against Methicillin-susceptible Staphylococcus aureus UC9213	2000	Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5	Substituent effects on the antibacterial activity of nitrogen-carbon-linked (azolylphenyl)oxazolidinones with expanded activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis.
AID206091	Minimum inhibitory concentration evaluated against Streptococci species [38]*	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID745376	Inhibition of human CYP2D6 assessed as dextromethorphan O-demethylation after 20 mins by LC/MS/MS analysis	2013	European journal of medicinal chemistry, May, Volume: 63	Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.
AID745381	Antibacterial activity against methicillin-resistant Staphylococcus aureus SR3637 infected in JCL/ICR mouse systemic infection model assessed as mortality administered as po measured over 7 days	2013	European journal of medicinal chemistry, May, Volume: 63	Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.
AID28085	Cmax value in Male Sprague-Dawley Rat at dose 10 (mg/kg iv)	2003	Journal of medicinal chemistry, Jan-16, Volume: 46, Issue:2	Identification of phenylisoxazolines as novel and viable antibacterial agents active against Gram-positive pathogens.
AID67754	Minimum inhibitory concentration against Enterococcus faecalis MTCC 439	2004	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12	Oxazolidinone: search for highly potent antibacterial.
AID262238	Antibacterial activity against penicillin-resistant Streptococcus pneumoniae ATCC 700904	2006	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6	Novel 4-N-substituted aryl pent-2-ene-1,4-dione derivatives of piperazinyloxazolidinones as antibacterials.
AID133290	Minimum inhibitory concentration of the subcutaneously administered compound evaluated against Enterococci faecalis D2HT6 strain in mice	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID319149	Oral bioavailability in rat at 25 mg/kg	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections.
AID383560	Antibacterial activity against Staphylococcus aureus ATCC 25923 by broth microdilution technique	2008	European journal of medicinal chemistry, Apr, Volume: 43, Issue:4	Synthesis and in vitro antibacterial activities of novel oxazolidinones.
AID244813	Minimum inhibitory concentration against Enterococcus faecium A24885	2005	Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11	Synthesis and antibacterial activity of dihydro-1,2-oxazine and 2-pyrazoline oxazolidinones: novel analogs of linezolid.
AID66559	Minimum inhibitory concentration evaluated against enterococci species resistant to vancomycin [65]*	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	28 (50.91)	18.2507
2000's	20 (36.36)	29.6817
2010's	5 (9.09)	24.3611
2020's	2 (3.64)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (1.72%)	5.53%
Reviews	6 (10.34%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	51 (87.93%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
gentamicin Gentamicins: A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS.	7.01	1	0
isoniazid Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).	3.14	1	0	carbohydrazide	antitubercular agent; drug allergen
troglitazone Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.	2.03	1	0	chromanes; thiazolidinone	anticoagulant; anticonvulsant; antineoplastic agent; antioxidant; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; hypoglycemic agent; platelet aggregation inhibitor; vasodilator agent
chloramphenicol Amphenicol: Chloramphenicol and its derivatives.	6.99	1	0	C-nitro compound; carboxamide; diol; organochlorine compound	antibacterial drug; antimicrobial agent; Escherichia coli metabolite; geroprotector; Mycoplasma genitalium metabolite; protein synthesis inhibitor
methicillin Methicillin: One of the PENICILLINS which is resistant to PENICILLINASE but susceptible to a penicillin-binding protein. It is inactivated by gastric acid so administered by injection.. methicillin : A penicillin that is 6-aminopenicillanic acid in which one of the amino hydrogens is replaced by a 2,6-dimethoxybenzoyl group.	2.02	1	0	penicillin allergen; penicillin	antibacterial drug
penicillanic acid Penicillanic Acid: A building block of penicillin, devoid of significant antibacterial activity. (From Merck Index, 11th ed). penicillanic acid : A penam that consists of 3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane bearing a carboxy group at position 2 and having (2S,5R)-configuration.	1.99	1	0	penicillanic acids
nafcillin Nafcillin: A semi-synthetic antibiotic related to penicillin.. nafcillin : A penicillin in which the substituent at position 6 of the penam ring is a (2-ethoxy-1-naphthoyl)amino group.	1.99	1	0	penicillin allergen; penicillin	antibacterial drug
oxazoles Oxazoles: Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.. 1,3-oxazole : A five-membered monocyclic heteroarene that is an analogue of cyclopentadiene with O in place of CH2 at position 1 and N in place of CH at position 3.. oxazole : An azole based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom.	7.73	30	1	1,3-oxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
erythromycin Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.	2	1	0	cyclic ketone; erythromycin
vancomycin Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.	5.62	14	0	glycopeptide	antibacterial drug; antimicrobial agent; bacterial metabolite
amoxicillin Amoxicillin: A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration.. amoxicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-(4-hydroxyphenyl)acetamido group.	1.99	1	0	penicillin allergen; penicillin	antibacterial drug
zidovudine Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.	2.03	1	0	azide; pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
ticarcillin Ticarcillin: An antibiotic derived from penicillin similar to CARBENICILLIN in action.. ticarcillin : A penicillin compound having a 6beta-[(2R)-2-carboxy-2-thiophen-3-ylacetyl]amino side-group.	1.99	1	0	penicillin allergen; penicillin	antibacterial drug
adinazolam adinazolam: structure in first source. adinazolam : A triazolo[4,3-a][1,4]benzodiazepine having a dimethylaminomethyl group at the 1-position, a phenyl group at the 6-position and a chloro substituent at the 8-position.	2.03	1	0	triazolobenzodiazepine	anticonvulsant; antidepressant; anxiolytic drug; sedative
diltiazem Diltiazem: A benzothiazepine derivative with vasodilating action due to its antagonism of the actions of CALCIUM ion on membrane functions.. diltiazem : A 5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate in which both stereocentres have S configuration. A calcium-channel blocker and vasodilator, it is used as the hydrochloride in the management of angina pectoris and hypertension.	2.03	1	0	5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate	antihypertensive agent; calcium channel blocker; vasodilator agent
piperacillin Piperacillin: Semisynthetic, broad-spectrum, AMPICILLIN derived ureidopenicillin antibiotic proposed for PSEUDOMONAS infections. It is also used in combination with other antibiotics.. piperacillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carboxamido]-2-phenylacetamido group.	1.99	1	0	penicillin allergen; penicillin	antibacterial drug
clinafloxacin clinafloxacin: structure given in first source; RN given is for monoHCl	3.09	1	0	quinolines
trovafloxacin trovafloxacin: a trifluoronaphthyridone derivative of 7-(3-azabicyclo(3.1.0)hexyl)naphthyridone; has antineoplastic activity. trovafloxacin : A 1,8-naphthyridine derivative that is 4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid bearing additional 2,4-difluorophenyl, fluoro and 6-amino-3-azabicyclo[3.1.0]hex-3-yl substituents at positions 1, 6 and 7 respectively. A broad-spectrum antibiotic that was withdrawn from the market due to risk of liver failure.	3.78	3	0
cephalosporin c cephalosporin C: RN given refers to parent cpd; structure in Merck, 9th ed, #1937. cephalosporin C : A cephalosporin antibiotic carrying a 3-acetoxymethyl substituent and a 6-oxo-N(6)-L-lysino group at position 7.	1.99	1	0	cephalosporin	fungal metabolite
oxazolidin-2-one Oxazolidinones: Derivatives of oxazolidin-2-one. They represent an important class of synthetic antibiotic agents.. oxazolidin-2-one : An oxazolidinone that is 1,3-oxazolidine with an oxo substituent at position 2.. oxazolidinone : An oxazolidine containing one or more oxo groups.	7.86	34	1	carbamate ester; oxazolidinone	metabolite
imipenem, anhydrous Imipenem: Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.. imipenem : A broad-spectrum, intravenous beta-lactam antibiotic of the carbapenem subgroup.	3.09	1	0	beta-lactam antibiotic allergen; carbapenems; zwitterion	antibacterial drug
methotrexate [no description available]	3.27	1	0	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
abt 719 [no description available]	3.09	1	0
puromycin [no description available]	1.99	1	0	puromycins	antiinfective agent; antimicrobial agent; antineoplastic agent; EC 3.4.11.14 (cytosol alanyl aminopeptidase) inhibitor; EC 3.4.14.2 (dipeptidyl-peptidase II) inhibitor; nucleoside antibiotic; protein synthesis inhibitor
n-formylmethionine N-formyl-L-methionine : A L-methionine derivative in which one of the hydrogens attached to the nitrogen is replaced by a formyl group.	1.99	1	0	L-methionine derivative; N-formyl amino acid; proteinogenic amino acid	metabolite
linezolid [no description available]	8.72	45	1	acetamides; morpholines; organofluorine compound; oxazolidinone	antibacterial drug; protein synthesis inhibitor
mupirocin Mupirocin: A topically used antibiotic from a strain of Pseudomonas fluorescens. It has shown excellent activity against gram-positive staphylococci and streptococci. The antibiotic is used primarily for the treatment of primary and secondary skin disorders, nasal infections, and wound healing.. mupirocin : An alpha,beta-unsaturated ester resulting from the formal condensation of the alcoholic hydroxy group of 9-hydroxynonanoic acid with the carboxy group of (2E)-4-[(2S)-tetrahydro-2H-pyran-2-yl]-3-methylbut-2-enoic acid in which the tetrahydropyranyl ring is substituted at positions 3 and 4 by hydroxy groups and at position 5 by a {(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl}methyl group. Originally isolated from the Gram-negative bacterium Pseudomonas fluorescens, it is used as a topical antibiotic for the treatment of Gram-positive bacterial infections.	2	1	0	alpha,beta-unsaturated carboxylic ester; epoxide; monocarboxylic acid; oxanes; secondary alcohol; triol	antibacterial drug; bacterial metabolite; protein synthesis inhibitor
clindamycin Clindamycin: An antibacterial agent that is a semisynthetic analog of LINCOMYCIN.. clindamycin : A carbohydrate-containing antibiotic that is the semisynthetic derivative of lincomycin, a natural antibiotic.	2	1	0
zithromax Azithromycin: A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.. azithromycin : A macrolide antibiotic useful for the treatment of bacterial infections.	3.49	2	0	macrolide antibiotic	antibacterial drug; environmental contaminant; xenobiotic
sitafloxacin [no description available]	3.09	1	0	fluoroquinolone antibiotic; quinolines; quinolone antibiotic
u 100480 U 100480: structure given in first source	3.52	2	0
ranbezolid ranbezolid: structure in first source	2.03	1	0
lincomycin Lincomycin: An antibiotic produced by Streptomyces lincolnensis var. lincolnensis. It has been used in the treatment of staphylococcal, streptococcal, and Bacteroides fragilis infections.. lincomycin : A carbohydrate-containing antibiotic produced by the actinomyces Streptomyces lincolnensis.	6.99	1	0	carbohydrate-containing antibiotic; L-proline derivative; monocarboxylic acid amide; pyrrolidinecarboxamide; S-glycosyl compound	antimicrobial agent; bacterial metabolite
brl 28500 ticarcillin-clavulanic acid: combination of ticarcillin and clavulanic acid; used against gram-negative rods	1.99	1	0
evernimicin [no description available]	3.27	1	0
amoxicillin-potassium clavulanate combination Amoxicillin-Potassium Clavulanate Combination: A fixed-ratio combination of amoxicillin trihydrate and potassium clavulanate.	1.99	1	0
cefditoren cefditoren: structure given in first source; RN given refers to the (6R-(3(Z),6alpha,7beta(Z)))-isomer. cefditoren : A broad spectrum, third-generation cephalosporin antibiotic with (Z)-2-(4-methyl-1,3-thiazol-5-yl)ethenyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. Generally administered as its orally absorbed pivaloyloxymethyl ester prodrug, it is used for the treatment of mild to moderate infections caused by susceptible strains of microorganisms in acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia, pharyngitis/tonsillitis, and uncomplicated skin and skin-structure infections.	1.99	1	0	carboxylic acid; cephalosporin	antibacterial drug
virginiamycin Virginiamycin: A cyclic polypeptide antibiotic complex from Streptomyces virginiae, S. loidensis, S. mitakaensis, S. pristina-spiralis, S. ostreogriseus, and others. It consists of 2 major components, VIRGINIAMYCIN FACTOR M1 and virginiamycin Factor S1. It is used to treat infections with gram-positive organisms and as a growth promoter in cattle, swine, and poultry.. virginiamycin : A mixture of cyclic polypeptide streptogramin antibiotics produced by Streptomyces virginiae, S. loidensis, S. mitakaensis, S. pristina-spiralis, S. ostreogriseus, and others. The two major components are virginiamycin M1 (also known as pristinamycin IIA) and virginiamycin S1. Virginiamycin has been widely used as a growth promotion agent in livestock and has been to have bacteriostatic activity against Gram-positive organisms such as staphylococci and streptococci.	2.68	3	0
magainin 1 peptide, xenopus magainin I: Antibiotic peptide. Thought to preferentially bind to anionic phosholipids.	3.09	1	0
ge 2270 a GE 2270 A: from Planobispora rosea; inhibits bacterial protein synthesis in vitro by affecting specifically the GTP-bound form of elongation factor Tu; structure given in first source	3.09	1	0
ro13-9904 Ceftriaxone: A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears.. ceftriaxone : A third-generation cephalosporin compound having 2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetylamino and [(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl side-groups.	1.99	1	0
piperacillin, tazobactam drug combination Piperacillin, Tazobactam Drug Combination: An antibiotic combination product of piperacillin and tazobactam, a penicillanic acid derivative with enhanced beta-lactamase inhibitory activity, that is used for the intravenous treatment of intra-abdominal, pelvic, and skin infections and for community-acquired pneumonia of moderate severity. It is also used for the treatment of PSEUDOMONAS AERUGINOSA INFECTIONS.	1.99	1	0
quinupristin quinupristin: component of RP 59500; structure in first source	2	1	0	cyclodepsipeptide
quinupristin-dalfopristin quinupristin-dalfopristin: RP 59500 is a combination of RP 57669 & RP 54476, which are water soluble derivatives of pristinamycin IA & pristinamycin IIB, respectively	1.99	1	0	organic molecular entity
piperidines Piperidines: A family of hexahydropyridines.	2	1	0
novobiocin Novobiocin: An antibiotic compound derived from Streptomyces niveus. It has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase, and blocks adenosine triphosphatase (ATPase) activity. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189). novobiocin : A coumarin-derived antibiotic obtained from Streptomyces niveus.	2	1	0	carbamate ester; ether; hexoside; hydroxycoumarin; monocarboxylic acid amide; monosaccharide derivative; phenols	antibacterial agent; antimicrobial agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; Escherichia coli metabolite; hepatoprotective agent
minocycline Minocycline: A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.. minocycline : A tetracycline analogue having a dimethylamino group at position 7 and lacking the methyl and hydroxy groups at position 5.	3.09	1	0
clorobiocin clorobiocin: chlorine-containing antibiotic related to novobiocin	2	1	0
pf-06424439 PF-06424439: an inhibitor of diacylglycerol acyltransferase 2; structure in first source	3.27	1	0

Condition	Relationship Strength	Studies	Trials
Infections, Staphylococcal [description not available]	4.78	7	1
Staphylococcal Infections Infections with bacteria of the genus STAPHYLOCOCCUS.	4.78	7	1
Bacterial Infections, Gram-Positive [description not available]	5.69	4	1
Gram-Positive Bacterial Infections Infections caused by bacteria that retain the crystal violet stain (positive) when treated by the gram-staining method.	5.69	4	1
Congenital Zika Syndrome [description not available]	2.25	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.25	1	0
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	2.25	1	0
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2.03	1	0
Bacterial Disease [description not available]	1.99	1	0
Bacterial Infections Infections by bacteria, general or unspecified.	1.99	1	0
Infections, Pneumococcal [description not available]	3.79	2	1
Pneumococcal Infections Infections with bacteria of the species STREPTOCOCCUS PNEUMONIAE.	3.79	2	1
Koch's Disease [description not available]	2	1	0
Tuberculosis Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.	2	1	0
Middle Ear Inflammation [description not available]	2	1	0
Acute Disease Disease having a short and relatively severe course.	2	1	0
Otitis Media Inflammation of the MIDDLE EAR including the AUDITORY OSSICLES and the EUSTACHIAN TUBE.	2	1	0
Abscess, Abdominal [description not available]	2	1	0
Abdominal Abscess An abscess located in the abdominal cavity, i.e., the cavity between the diaphragm above and the pelvis below. (From Dorland, 27th ed)	7	1	0

eperezolid

Cross-References

Synonyms (38)

Research Excerpts

Pharmacokinetics

Bioavailability

Dosage Studied

Protein Targets (5)

Potency Measurements

Inhibition Measurements

Biological Processes (41)

Molecular Functions (33)

Ceullar Components (6)

Bioassays (217)

Research

Studies (55)

Market Indicators

Research Demand Index: 23.49

Study Types

eperezolid

Cross-References

Synonyms (38)

Research Excerpts

Pharmacokinetics

Bioavailability

Dosage Studied

Protein Targets (5)

Potency Measurements

Inhibition Measurements

Biological Processes (41)

Molecular Functions (33)

Ceullar Components (6)

Bioassays (217)

Research

Studies (55)

Market Indicators

Research Demand Index: 23.49

Study Types

Related Drugs (49)

Related Conditions (19)